Home News Antares Pharma -30% as FDA finds deficiencies in Xyosted NDA – Antares...

Antares Pharma -30% as FDA finds deficiencies in Xyosted NDA – Antares Pharma Inc. (NASDAQ:ATRS)

9
0
SHARE


Antares Pharma (NASDAQ:ATRS) -29.7% after-hours on news that the FDA had identified deficiencies as part of a review of the company’s new drug application for Xyosted (testosterone enanthate).

ATRS says the FDA did not specify the deficiencies but would prevent continuing with labeling and postmarketing requirements and commitments.

ATRS first submitted the Xyosted NDA in December 2016.



Source link

LEAVE A REPLY